{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:40:32Z","timestamp":1770792032778,"version":"3.50.0"},"reference-count":33,"publisher":"SLACK, Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Objective:<\/jats:title>\n                    <jats:p>The DRCR Retina Network Protocol S established anti-vascular endothelial growth factor (anti-VEGF) therapy as non-inferior to panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR). This study examines PDR treatment trends in the United States from 2016 to 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This retrospective study used the TriNetX US Collaborative Network to identify PDR patients diagnosed between 2016 and 2023. Patients were stratified by treatment type (anti-VEGF, laser\/PRP, or both) and demographic factors. Treatment rates were analyzed using prevalence ratios (PRs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>From 2016 to 2023, laser\/PRP treatment rates decreased (PR 0.76, CI 0.71\u20130.80), while anti-VEGF (PR 1.61, CI 1.52\u20131.71) and combination treatment rates (PR 1.21, CI 1.12\u20131.32) increased. Hispanic patients had declining anti-VEGF rates during 2020 to 2023 but had higher laser rates than White patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>There is a growing preference for multimodal treatment, though single therapies remain dominant. Disparities among minority groups warrant further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3928\/23258160-20251111-01","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T18:47:58Z","timestamp":1768330078000},"page":"94-100","source":"Crossref","is-referenced-by-count":0,"title":["Trends in the Use of Laser and Anti-Vascular Endothelial Growth Factor Injection for Proliferative Diabetic Retinopathy in the United States"],"prefix":"10.3928","volume":"57","author":[{"given":"Xinyu","family":"Gu","sequence":"first","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia J.","family":"Abbass","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio;"},{"name":"Cleveland Clinic Cole Eye Institute, Departments of Internal Medicine, Pediatrics, Cleveland, Ohio;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[{"name":"Population and Quantitative Health Sciences, Case Western Reserve University, The Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cole Eye Institute, Departments of Internal Medicine, Pediatrics, Cleveland, Ohio;"},{"name":"Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio;"},{"name":"Cleveland Clinic Martin Hospitals, Cleveland Clinic Florida, Stuart, Florida;"},{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cole Eye Institute, Departments of Internal Medicine, Pediatrics, Cleveland, Ohio;"},{"name":"Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio;"},{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15217"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.3255"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.07.018"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1834"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.0052"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.9.735"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S170089"},{"key":"e_1_3_1_9_2","article-title":"Breaking news: FDA approves faricimab for treatment of wet AMD, DME","author":"Hutton D","unstructured":"Hutton D; OT Staff Reports. Breaking news: FDA approves faricimab for treatment of wet AMD, DME. Ophthalmol Times. Published January 29, 2022. Accessed September 9, 2024. https:\/\/www.ophthalmologytimes.com\/view\/breaking-news-fda-approves-faricimab-for-treatment-of-wet-amd-dme","journal-title":"Ophthalmol Times"},{"key":"e_1_3_1_10_2","article-title":"FDA approves brolucizumab for diabetic macular edema","author":"Harrison L","unstructured":"Harrison L. FDA approves brolucizumab for diabetic macular edema. Medscape. Published June 8, 2022. Accessed September 9, 2024. https:\/\/www.medscape.com\/viewarticle\/975248","journal-title":"Medscape"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051413"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.5248"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.08.004"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.1844"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1038757"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.709501"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034856"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14681"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2407037"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.807687"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19063481"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-6306"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20220615-01"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.05.005"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.04.016"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.3528"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2022.101739"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.07.027"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2017.30"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110069"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.09.025"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S314840"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011234.pub2"},{"key":"e_1_3_1_34_2","article-title":"Long-term outcomes of anti-VEGF therapy","author":"Cuilla TA","unstructured":"Cuilla TA, Hussain RM. Long-term outcomes of anti-VEGF therapy. Retina Today. Published November 2021. Accessed February 27, 2025. https:\/\/retinatoday.com\/articles\/2021-nov-dec\/long-term-outcomes-of-anti-vegf-therapy","journal-title":"Retina Today"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T21:31:14Z","timestamp":1770759074000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20251111-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.3928\/23258160-20251111-01"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20251111-01","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}